Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia: Results from Two Phase 2 Studies

Plain-language guide to PMID 34146101 (2021): open-label clinical trial, phase ii study of ACTH (Corticotropin) and CRH (Corticotropin-Releasing Hormone), hyperparathyroidism.

Key Facts

PMID: 34146101
Journal: The Journal of clinical endocrinology and metabolism
Year: 2021
Study type: Clinical Trial, Phase II
Authors: Sarafoglou K et al. (11 authors)
DOI: 10.1210/clinem/dgab438

What This Study Did, in Plain Language

What Was Tested

Researchers studied ACTH (Corticotropin) and CRH (Corticotropin-Releasing Hormone) in the context of hyperparathyroidism in this clinical trial, phase ii publication.

Who Took Part

By PubMed's age tags, the people studied were young adults, adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The researchers set it up as a open-label study.

Being open-label, the ACTH (Corticotropin) study did not mask who received what.

Two Phase 2 open-label studies.

What Was Measured

The subject headings attached to it are 17-alpha-Hydroxyprogesterone, Adrenal Hyperplasia, Congenital, Adrenocorticotropic Hormone, Androstenedione, Biomarkers, Receptors, Corticotropin-Releasing Hormone and CRF Receptor, Type 1.

The authors tagged it with the keywords 17-hydroxyprogesterone, CRF-receptor antagonist, congenital adrenal hyperplasia and tildacerfont.

What This Means in Plain Language

The paper is an open-label study of ACTH (Corticotropin) and CRH (Corticotropin-Releasing Hormone) in people with hyperparathyroidism.

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2021 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the ACTH (Corticotropin) compound page and the CRH (Corticotropin-Releasing Hormone) compound page, Hyperparathyroidism research.

Our Notes on the Compounds

ACTH (Corticotropin): The 39-amino-acid pituitary hormone that drives cortisol production; given as repository corticotropin (Acthar Gel).

CRH (Corticotropin-Releasing Hormone): The 41-amino-acid hypothalamic hormone that triggers ACTH release; corticorelin is used diagnostically.

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.